• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    BioCryst Pharmaceuticals, Inc. - Common Stock (NQ:BCRX)

    8.755 +0.135 (+1.57%)
    Streaming Delayed Price Updated: 11:32 AM EDT, Mar 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,229,034
    Open 8.630
    Bid (Size) 8.750 (600)
    Ask (Size) 8.760 (1,600)
    Prev. Close 8.620
    Today's Range 8.630 - 8.840
    52wk Range 6.000 - 11.31
    Shares Outstanding 185,583,896
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Shatters Q4 2025 Estimates with Stellar Earnings Beat ↗
    Via Chartmill
    Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today? ↗
    Via Stocktwits

    Performance

    YTD
    +16.7%
    +16.7%
    1 Month
    +39.0%
    +39.0%
    3 Month
    +13.7%
    +13.7%
    6 Month
    +6.9%
    +6.9%
    1 Year
    +18.6%
    +18.6%

    More News

    Read More
    News headline image
    Why Dyne Therapeutics Stock Was Crushing it This Week ↗
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
    From Astria Therapeutics, Inc.
    Via Business Wire
    News headline image
    BioCryst (BCRX) Q3 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Earnings Scheduled For November 3, 2025 ↗
    Via Benzinga
    BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play ↗
    Via Stocktwits
    BioCryst To Acquire Astria Therapeutics In $700M Deal ↗
    Via Stocktwits
    News headline image
    Top Stocks With Earnings This Week: Joby, IonQ, AMD and More ↗
    Via Benzinga
    News headline image
    BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Posts Mixed Q3 2025 Results, Beats on EPS But Misses Revenue ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Earnings Scheduled For August 4, 2025 ↗
    Via Benzinga
    News headline image
    Earnings Outlook For BioCryst Pharma ↗
    Via Benzinga
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sotherly Hotels Inc. (Nasdaq – SOHO), Hologic, Inc. (Nasdaq – HOLX), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hologic, Inc. (Nasdaq – HOLX), TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TrueCar, Inc. (Nasdaq – TRUE), Astria Therapeutics, Inc. (Nasdaq – ATXS), PotlatchDeltic Corporation (Nasdaq – PCH), SWK Holdings Corporation (Nasdaq – SWKH)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
    Via Benzinga
    News headline image
    BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate' ↗
    Via Benzinga
    News headline image
    BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
    From Astria Therapeutics, Inc.
    Via Business Wire
    News headline image
    Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
    Via MarketMinute
    News headline image
    Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder ↗
    Via Benzinga
    News headline image
    BioCryst Eyes Strengthening Pipeline After Upbeat Q2 Earnings: Retail Thinks Fair Valuation For Stock Is Double The Current Level ↗
    Via Stocktwits
    Topics Artificial Intelligence Earnings
    News headline image
    BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Exceeds Q2 2025 Expectations with Robust Revenue and Profit Growth ↗
    Via Chartmill
    News headline image
    BioCryst (BCRX) Q2 Revenue Jumps 50% ↗
    Via The Motley Fool
    News headline image
    BioCryst Just Ditched Its Europe Business — Here's Why Investors Are Cheering ↗
    Via Benzinga
    News headline image
    BioCryst To Sell European Business Of Its Hereditary Angioedema Drug To Pay Off Debt: Stock Rises While Retail Stays Bearish ↗
    Via Stocktwits

    Frequently Asked Questions

    Is BioCryst Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, BioCryst Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does BioCryst Pharmaceuticals, Inc. - Common Stock trade on?
    BioCryst Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for BioCryst Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for BioCryst Pharmaceuticals, Inc. - Common Stock is BCRX on the Nasdaq Stock Market
    What is the current price of BioCryst Pharmaceuticals, Inc. - Common Stock?
    The current price of BioCryst Pharmaceuticals, Inc. - Common Stock is 8.755
    When was BioCryst Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of BioCryst Pharmaceuticals, Inc. - Common Stock was at 03/10/26 11:32 AM ET
    What is the market capitalization of BioCryst Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of BioCryst Pharmaceuticals, Inc. - Common Stock is 1.62B
    How many shares of BioCryst Pharmaceuticals, Inc. - Common Stock are outstanding?
    BioCryst Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.